Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

November 12, 2013

Primary Completion Date

October 2, 2023

Study Completion Date

October 2, 2023

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

Natalizumab

As described in the treatment arm.

Trial Locations (18)

2720-276

Research Site, Amadora

9700-049

Research Site, Angra do Heroísmo

3810-164

Research Site, Aveiro

4710-243

Research Site, Braga

3004-561

Research Site, Coimbra

8000-386

Research Site, Faro

9000-177

Research Site, Funchal

4835-044

Research Site, Guimarães

2410-197

Research Site, Leiria

1649-028

Research Site, Lisbon

2674-514

Research Site, Loures

4450-021

Research Site, Matosinhos Municipality

4564-007

Research Site, Penafiel

4200-319

Research Site, Porto

4520-220

Research Site, Santa Maria da Feira

2910-446

Research Site, Setúbal

4904-858

Research Site, Viana do Castelo

4434-502

Research Site, Vila Nova de Gaia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT04832399 - Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants | Biotech Hunter | Biotech Hunter